Is the treatment effect of venetoclax (venetoclax) good?

Venetoclax (also known as Venetoclax) is a BCL-2 inhibitor jointly developed by AbbVie (AbbVie) and Genentech (Genentech). It is mainly used to treat certain types of hematological malignancies. Its main mechanism is to promote the natural death of cancer cells by inhibiting BCL-2 protein, an anti-apoptotic factor. For patients with chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), especially those carrying high-risk mutations, venetoclax has shown significant anti-tumor activity and clinical benefit.

Venetoclax has been widely recognized for its efficacy in clinical trials and real-world studies. For patients with chronic lymphocytic leukemia, venetoclax combined with drugs such as azacitidine or rituximab can significantly extend progression-free survival and achieve a higher complete remission rate in some cases. For elderly or frail patients with acute myeloid leukemia who are not suitable for intensive chemotherapy, the drug has also achieved significant results when combined with low-dose chemotherapy, giving many patients a chance of remission and extending their survival.

However, venetoclax may induce tumor lysis syndrome (TLS) in the early stages of use, especially in patients with high white blood cell counts or large tumor burdens, so gradual dose increase and close monitoring are required. In addition, the side effects of this drug mainly include neutropenia, anemia, infection, etc. During the medication period, patients need to undergo routine tests such as blood picture and liver and kidney function. Reasonable dose adjustment and supportive treatment are the keys to ensuring efficacy and safety.

Taken together, venetoclax is effective in certain hematological tumors, especially in high-risk or treatment-failed patients, showing superior survival benefits. With the continuous optimization of combination drug strategies, venetoclax is gradually shifting from a "life-saving drug" to a more conventional treatment option. For suitable people, venetoclax is one of the important breakthroughs in the current field of hematological cancer treatment.

Reference materials:https://www.venclexta.com/